Page 7,123«..1020..7,1227,1237,1247,125..7,1307,140..»

Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings

Posted: Published on February 17th, 2012

GAITHERSBURG, MD--(Marketwire -02/16/12)- Cytomedix, Inc. (OTC.BB: CMXI.OB - News) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Chief Operating Officer Edward L. Field will present a clinical overview of Aldagen's autologous cell therapy technology at two upcoming meetings: The Cell Society's 2nd Annual Clinical Meeting being held February 17-18 at the Coronado Marriott Resort in San Diego; and the 7th Annual New York Stem Cell Summit being held on February 21 at Bridgewaters New York in New York City. Mr. Field will present during the session, "Commercialization Opportunities with Adult Stem Cell Therapies," on Friday, February 17 from 8:00 a.m. to 10:00 a.m. Pacific time at the Cell Society meeting. Cell Society International is a non-profit organization dedicated to advancing the clinical application of adult stem cell therapies worldwide. Cell Society's 2nd Annual Clinical Meeting will continue in the tradition established at the 1st Annual Meeting and will offer a unique opportunity for multidisciplinary, international clinical collaboration designed to enhance understanding and thought-provoking insight into treatments and cures for disease and agonizing medical conditions. This year's clinical focus will center on therapies particularly relevant to cardiology, neurology, and orthopedic … Continue reading →

Comments Off on Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings

Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss

Posted: Published on February 17th, 2012

SAN BRUNO, Calif., Feb. 16, 2012 /PRNewswire/ -- Cord Blood Registry (CBR) is the exclusive partner for a growing number of clinical researchers focusing on the use of a child's own cord blood stem cells to help treat pediatric brain injury and acquired hearing loss. To ensure consistency in cord blood stem cell processing, storage and release for infusion, three separate trials have included CBR in their FDA-authorized protocol—including two at the University of Texas Health Science Center at Houston (UTHealth) working in partnership with Children's Memorial Hermann Hospital, and a third at Georgia Health Sciences University, home of the Medical College of Georgia (MCG). This makes CBR the only family stem cell bank pairing researchers with prospective patients for these studies.  (Logo: http://photos.prnewswire.com/prnh/20120216/AQ54476LOGO) "Partnering with a series of specialists who want to research the use of a child's own newborn blood stem cells on a variety of disease states allows CBR to help advance medical research for regenerative therapies by connecting the child whose family banked with CBR to appropriate researchers," said Heather Brown, MS, CGC, Vice President of Scientific & Medical Affairs at Cord Blood Registry.  "The pediatric specialists from UTHealth, Children's Memorial Hermann Hospital, and Georgia Health Sciences … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss

MissionIR News – VistaGen Therapeutics Selects Top 10 Candidates for Stem Cell Technology-Based Drug Rescue Programs

Posted: Published on February 17th, 2012

Company plans launch of two drug rescue programs by end of next quarter Atlanta, GA (PRWEB) February 16, 2012 MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. In the company’s news this week, VistaGen announced the identification of its initial Top 10 drug rescue candidates. The company plans to launch two formal drug rescue programs by the end of next quarter. VistaGen’s goal for each of its stem cell technology-based drug rescue programs is to generate and license a new, safer variant of a once-promising large market drug candidate previously discontinued by a pharmaceutical company no earlier than late-preclinical development. “We are now at an advanced stage in our business model,” stated Shawn Singh, VistaGen’s Chief Executive Officer. “After more than a decade of … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on MissionIR News – VistaGen Therapeutics Selects Top 10 Candidates for Stem Cell Technology-Based Drug Rescue Programs

Histogenics to Present at 7th Annual New York Stem Cell Summit

Posted: Published on February 17th, 2012

WALTHAM, Mass.--(BUSINESS WIRE)-- Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated. Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011. About Histogenics Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly … Continue reading →

Comments Off on Histogenics to Present at 7th Annual New York Stem Cell Summit

World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

Posted: Published on February 17th, 2012

World Stem Cells, LLC Stem Cell Therapy at a state of the art clinic in beautiful Cancun. The clinic is staffed by top specialist in the field of stem cell implants and a new laboratory to support the stem cell treatments given. (PRWEB) February 16, 2012 World Stem Cells, LLC. contract laboratory Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.) a new adult stem cell laboratory being built in Cancun, Mexico to support Stem Cell research, stem cell clinical trials and stem cell treatments. This was accomplished by private funding in conjunction with World Stem Cells, LLC worldstemcells.com a US patient management company, Medicina Biocelular Avanzada , S.E. de C.V. a Mexican patient management company and Advanced Cellular Medicine Clinic of Cancun, a Stem Cell treatment Clinic owned and operated by Dr. Sylvia M. Abblitt a well known board certified hematologist and oncologist, in Cancun. Uniquely, Dr. Abblitt is one of a limited number of physicians licensed to perform autologous and allogeneic stem cell transplants. Dr. Abblitt has been utilizing stem cell therapies with successes for many years. She is the president and lab director of Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.). Her extensive … Continue reading →

Comments Off on World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

Pathfinder to Present at New York Stem Cell Summit

Posted: Published on February 17th, 2012

CAMBRIDGE, Mass., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, will present at the 7th Annual New York Stem Cell Summit being held on Tuesday, February 21, 2012. Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET Dr. Franklin will be providing an overview of the Company's novel Pathfinder Cell therapy. The New York Stem Cell Summit brings together stem cell company executives, researchers, investors and physicians to explore investment opportunities in stem cell research and innovation. More information can be found at http://www.stemcellsummit.com. About Pathfinder Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells ("PCs") Pathfinder is pioneering a new field in regenerative medicine. PCs are a newly identified mammalian cell type present in … Continue reading →

Comments Off on Pathfinder to Present at New York Stem Cell Summit

Histogenics to Present at 7th Annual New York Stem Cell Summit

Posted: Published on February 17th, 2012

WALTHAM, Mass.--(BUSINESS WIRE)-- Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated. Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011. About Histogenics Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly … Continue reading →

Posted in Cell Medicine | Comments Off on Histogenics to Present at 7th Annual New York Stem Cell Summit

FDA Warns HCG is Dangerous, MS Bans Prescriptions

Posted: Published on February 17th, 2012

Zaneta Lowe 5:42 p.m. CST, February 16, 2012 FAST FACTS: HCG combined with a low calorie diet often leads to quick weight loss. The FDA banned OTC HCG products, but you can still find them. Mississippi doctors can't prescribe it for weight loss anymore.   (Memphis 2/16/2012) "I was obese, I weighed 285 pounds." Over the last six months, 57-year-old Jack Hammers has dropped 80 pounds. "Pants went from a 46 to a 36," says Hammers. Hammers says he owes it all to the HCG diet. First created in the 1950s, the diet combines the use of daily HCG injections with eating only 500 calories a day.   Hammers and his wife Alice tried it together. She's lost 30 pounds. "You keep each other motivated," Alice says. The HCG diet has recently re-surged in popularity. There are weight loss clinics all across the country and here in the MidSouth. Dr. James "Bo" Adams has prescribed HCG for about 200 patients since he added the weight loss clinic to his practice more than a year ago. "We looked into it and thought, that might be a reasonable thing to offer to patients because obesity is a health care issue," says Adams. In … Continue reading →

Posted in Prescriptions | Comments Off on FDA Warns HCG is Dangerous, MS Bans Prescriptions

Remote-controlled drug implant

Posted: Published on February 17th, 2012

Remote-controlled drug implant Medication via remote-control instead of a shot? Scientists implanted microchips in seven women that did just that, oozing out the right dose of a bone-strengthening drug once a day without them even noticing. Implanted medicine is a hot field, aiming to help patients better stick to their medications and to deliver those drugs straight to the body part that needs them. But Thursday's study is believed to be the first attempt at using a wirelessly controlled drug chip in people. If this early-stage testing eventually pans out, the idea is that doctors one day might program dose changes from afar with the push of a button, or time them for when the patient is sleeping to minimise side effects. The implant initially is being studied to treat severe bone-thinning osteoporosis. But it could be filled with other types of medication, said co-inventor Robert Langer of the Massachusetts Institute of Technology. "It's like Star Trek," said Langer, referring to a science fiction television series. He co-authored the study appearing on Thursday in the journal, Science Translational Medicine. "Just send a signal over a special radio wave, and out comes the drug." Today's medication implants continuously emit their drugs … Continue reading →

Posted in Drug Side Effects | Comments Off on Remote-controlled drug implant

Implanted Chip Delivers Drugs Without a Thought

Posted: Published on February 17th, 2012

Researchers say they have made the first implantable chip that can deliver medicine for as long as a year and that several women tolerated it safely for up to four months. Not only did the subjects find the implant comfortable, but it appeared to deliver an osteoporosis drug effectively, the team told a meeting of the American Association for the Advancement of Science. They think such a device could be programmed to deliver a precise dose daily, helping to avoid problems caused when people fail to take their drugs on time. It could also be controlled remotely, allowing doctors to change dosage. “We see this as a new future for how doctors will administer drugs and how patients will receive their treatments,” Robert Farra of Massachusetts-based MicroCHIPS told a news conference. “Patients will be freed from having to remember to take their medication and don’t have to experience the pain of multiple injections.” Patients often fail to take medicines correctly -- and the more complex and expensive the drug, the less likely they are to remember. It's a headache for doctors and insurers alike, who end up spending needless time and money to treat symptoms that could have been prevented … Continue reading →

Posted in Drugs | Comments Off on Implanted Chip Delivers Drugs Without a Thought

Page 7,123«..1020..7,1227,1237,1247,125..7,1307,140..»